Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (61-70 of 209) with videos related to

Pageof 21
Sort By:
Clinical Lung Cancer|May 5, 2010
Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II studyDaniel Chua, Maciej Krzakowski, Christos Chouaid, et al.
BMC Cancer|July 24, 2012
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)Christos Chouaid, Hervé Le Caer, Chrystelle Locher, et al.
Therapie|August 5, 2006
[Medico economic analysis in first line chemotherapy in advanced lung cancer]Anne-Christine Joly, Géraldine Austruy-Chalendard, Sandra Camps, et al.
Current Medical Research and Opinion|October 6, 2011
An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancerMark J C Nuijten, Rick Aultman, Javier de Castro Carpeño, et al.
Oncotargets and Therapy|June 5, 2024
Characterization of Patients with <i>EGFR</i> Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in FranceMateo Sanchis-Borja, Florian Guisier, Aurélie Swalduz, et al.
Expert Review of Anticancer Therapy|September 4, 2018
Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic reviewPaul Lesueur, Isabelle Martel-Laffay, Alexandre Escande, et al.
Respiratory Medicine and Research|June 12, 2023
Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapyClarisse Audigier Valette, Thomas Filleron, Didier Debieuvre, et al.
Expert Review of Anticancer Therapy|August 30, 2017
Second-line treatments of small-cell lung cancersNathalie Baize, Isabelle Monnet, Laurent Greillier, et al.
Targeted Oncology|June 19, 2017
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung CancerOlivier Bylicki, Nicolas Paleiron, Jacques Margery, et al.
JTO Clinical and Research Reports|September 30, 2021
Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLCFerréol Roborel de Climens, Christos Chouaid, Claire Poulet, et al.
Pageof 21

Showing results (61-70 of 209) with videos related to

Sort By:
Pageof 21
Clinical Lung Cancer|May 5, 2010
Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II studyDaniel Chua, Maciej Krzakowski, Christos Chouaid, et al.
BMC Cancer|July 24, 2012
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)Christos Chouaid, Hervé Le Caer, Chrystelle Locher, et al.
Therapie|August 5, 2006
[Medico economic analysis in first line chemotherapy in advanced lung cancer]Anne-Christine Joly, Géraldine Austruy-Chalendard, Sandra Camps, et al.
Current Medical Research and Opinion|October 6, 2011
An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancerMark J C Nuijten, Rick Aultman, Javier de Castro Carpeño, et al.
Oncotargets and Therapy|June 5, 2024
Characterization of Patients with <i>EGFR</i> Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in FranceMateo Sanchis-Borja, Florian Guisier, Aurélie Swalduz, et al.
Expert Review of Anticancer Therapy|September 4, 2018
Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic reviewPaul Lesueur, Isabelle Martel-Laffay, Alexandre Escande, et al.
Respiratory Medicine and Research|June 12, 2023
Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapyClarisse Audigier Valette, Thomas Filleron, Didier Debieuvre, et al.
Expert Review of Anticancer Therapy|August 30, 2017
Second-line treatments of small-cell lung cancersNathalie Baize, Isabelle Monnet, Laurent Greillier, et al.
Targeted Oncology|June 19, 2017
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung CancerOlivier Bylicki, Nicolas Paleiron, Jacques Margery, et al.
JTO Clinical and Research Reports|September 30, 2021
Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLCFerréol Roborel de Climens, Christos Chouaid, Claire Poulet, et al.
Pageof 21